ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Novartis' $305,000 cancer drug covered by Japan health insurance

Leukemia treatment raises concerns over financial strain on system

Novartis' Kymriah CAR-T cell therapy for treating leukemia patients (Photo courtesy of Novartis)

TOKYO -- Japan's national medical insurance system was given the go-ahead on Wednesday to cover leukemia treatment using expensive Kymriah from Swiss drugmaker Novartis.

The Central Social Insurance Medical Council, a panel of the Ministry of Health, Labor and Welfare, approved coverage of the treatment, which costs 33.49 million yen ($305,455).

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more